Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dally

Showing results (541-550 of 579) with videos related to

Pageof 58
Sort By:
Vaccine|January 26, 2007
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicityBarry S Peters, Walter Jaoko, Eftyhia Vardas, et al.
Southern African Journal of Infectious Diseases|February 9, 2023
Ebola outbreak in Guinea, 2021: Clinical care of patients with Ebola virus diseaseBoyo C Pare, Alseny M Camara, Aminata Camara, et al.
Nature Communications|January 25, 2025
Solvent-dripping modulated 3D/2D heterostructures for high-performance perovskite solar cellsXiaoming Chang, Randi Azmi, Tinghuan Yang, et al.
Journal of Virology|April 28, 2006
Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopesNilu Goonetilleke, Stephen Moore, Len Dally, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 2001
p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureasA M Redman, J S Johnson, R Dally, et al.
Frontiers in Immunology|June 10, 2017
A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine RegimensSven Kratochvil, Paul F McKay, Jakub T Kopycinski, et al.
Plos One|May 12, 2015
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African AdultsGloria Omosa-Manyonyi, Juliet Mpendo, Eugene Ruzagira, et al.
Frontiers in Immunology|March 10, 2017
A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization RegimesSarah Joseph, Killian Quinn, Aldona Greenwood, et al.
Molecular Therapy. Methods & Clinical Development|September 13, 2016
Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adultsGaudensia Mutua, Bashir Farah, Robert Langat, et al.
The Journal of Infectious Diseases|January 19, 2010
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)Hannah Kibuuka, Robert Kimutai, Leonard Maboko, et al.
Pageof 58

Showing results (541-550 of 579) with videos related to

Sort By:
Pageof 58
Vaccine|January 26, 2007
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicityBarry S Peters, Walter Jaoko, Eftyhia Vardas, et al.
Southern African Journal of Infectious Diseases|February 9, 2023
Ebola outbreak in Guinea, 2021: Clinical care of patients with Ebola virus diseaseBoyo C Pare, Alseny M Camara, Aminata Camara, et al.
Nature Communications|January 25, 2025
Solvent-dripping modulated 3D/2D heterostructures for high-performance perovskite solar cellsXiaoming Chang, Randi Azmi, Tinghuan Yang, et al.
Journal of Virology|April 28, 2006
Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopesNilu Goonetilleke, Stephen Moore, Len Dally, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 2001
p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureasA M Redman, J S Johnson, R Dally, et al.
Frontiers in Immunology|June 10, 2017
A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine RegimensSven Kratochvil, Paul F McKay, Jakub T Kopycinski, et al.
Plos One|May 12, 2015
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African AdultsGloria Omosa-Manyonyi, Juliet Mpendo, Eugene Ruzagira, et al.
Frontiers in Immunology|March 10, 2017
A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization RegimesSarah Joseph, Killian Quinn, Aldona Greenwood, et al.
Molecular Therapy. Methods & Clinical Development|September 13, 2016
Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adultsGaudensia Mutua, Bashir Farah, Robert Langat, et al.
The Journal of Infectious Diseases|January 19, 2010
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)Hannah Kibuuka, Robert Kimutai, Leonard Maboko, et al.
Pageof 58